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Abstract 
Mutations in the dystrophin (DMD) gene and consequent loss of dystrophin cause Duchenne 
muscular dystrophy (DMD). A promising therapy for DMD, single-exon skipping using 
antisense phosphorodiamidate morpholino oligomers (PMOs), currently confronts major issues 
that an antisense drug induces the production of functionally undefined dystrophin and may not 
be similarly efficacious among patients with different mutations. Accordingly, the applicability 
of this approach is limited to out-of-frame mutations. Here, using an exon-skipping efficiency 
predictive tool, we designed three different PMO-cocktail sets for exons 45-55 skipping aiming 
to produce a dystrophin form with preserved functionality as seen in milder/asymptomatic 
individuals with an in-frame exons 45-55 deletion. Of them, the most effective set was composed 
of select PMOs of which each efficiently skips an assigned exon in cell-based screening. Its 
combinational PMOs fitted to different deletions of immortalized DMD patient-muscle cells 
significantly induced exons 45-55-skipped transcripts with removing three, eight or ten exons 
and dystrophin restoration as represented by Western blotting. In vivo skipping of the maximum 
eleven human DMD exons was confirmed in humanized mice. The finding indicates that our 
PMO set can be used as mutation-tailored cocktails for exons 45-55 skipping and treat over 65% 
DMD patients carrying out-of- or in-frame deletions. 
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Introduction 
Duchenne muscular dystrophy (DMD), a lethal X-linked recessive neuromuscular disorder, is 
caused by mutations in the dystrophin (DMD) gene and the absence of dystrophin for 
maintaining muscle membrane integrity.
1
 Although the DMD gene is the largest known in 
humans consisting of 79 exons in 2.4 Mb, there exists a mutational hotspot ranging from exon 43 
to 55.
2
 Deletions are the most frequent mutations to occur and account for approx. 68% of cases.
3
 
Of them, severe DMD results from mostly out-of-frame deletions that do not allow for the 
production of dystrophin. In contrast, in-frame deletions, which permits the production of 
internally-truncated dystrophins, mostly give rise to the mild counterpart, Becker muscular 
dystrophy (BMD).
4
 
These DMD genotype-phenotype associations provide the rationale of a promising 
therapy, exon skipping using synthetic nucleic acid analogs called antisense oligonucleotides 
(AOs). The current approach targets a single exon and aims to transform DMD-related 
out-of-frame mRNAs into in-frame ones, enabling the expression of truncated dystrophin as seen 
in BMD. In 2016, the first exon 51-skipping AO drug with the phosphorodiamidate morpholino 
oligomer (PMO) chemistry, though conditional, has been approved by the US Food and Drug 
Association (FDA)
5
 and clinical trials with other PMO-based AOs that target exon 45 or 53 are 
currently ongoing.
6, 7
 As such, PMO-mediated single-exon skipping has great promise for 
treating DMD. 
In this approach, however, a couple of major issues are raised. Single-exon skipping 
has not been fully correlated with functional correction of dystrophin. Dystrophin functionality 
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fluctuates in response to the structural difference between the resulting products.
8
 Indeed, it has 
been reported that clinical severity of BMD patients who have truncated dystrophin as seen 
following single-exon skipping vary depending on their in-frame patterns.
9-12 This creates a 
serious concern that an AO drug may not necessarily provide its expected therapeutic benefit 
equally across patients even though the same target exon is removed. Due to this uncertainty, the 
applicability is currently limited to DMD patients with out-of-frame deletions despite the fact 
that DMD is found at 22% of those with in-frame deletions.
2
  
Exons 45-55 skipping using AO cocktails is expected to overcome these limitations in 
single-exon skipping therapies.
13
 This multi-exon skipping strategy intends to produce a 
consistent dystrophin form with preserved functionality as seen in exceptionally milder or 
asymptomatic subjects carrying an exons 45-55 deletion.
11,13-18
 The exons 45-55-deleted 
dystrophin supposedly provides a favorable outcome among patients with different mutations. As 
demonstrated in pre-clinical studies, the strategy is achieved by excluding all the target exons 
from one mRNA at the same time and thus, success in treatment largely relies on the ability of 
respective AOs in a cocktail to skip a given exon within the region.
19-21
 A ready-to-use cocktail 
set composed of such effective AOs could serve as tailored medication to different deletions for 
treating DMD patients. 
In this study, for the first time, we demonstrated using the Leiden DMD database, that 
the exons 45-55 deletion is statistically associated with the occurrence of the mild BMD 
phenotype. The database analysis also revealed that a variety of AO combinations, in particular, 
those to skip ten and eight exons, are needed in exons 45-55 skipping therapy. Accordingly, the 
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applicability was shown to reach to more than 65% of DMD patients with out-of- and in-frame 
deletions. Given the need for tailored cocktail treatment, we designed three different cocktail sets 
composed of PMO-based AOs using an exon-skipping efficiency predictive tool we developed 
previously.
22
 Of them, the most effective cocktail set was one formulated with select PMOs 
which each efficiently skipped an assigned exon in in vitro screening. Derivative PMO cocktails 
from this set significantly skipped up to ten exons in immortalized DMD muscle cell lines, 
accompanied by dystrophin restoration as represented by Western blotting. In a mouse model 
having the normal human DMD gene, we demonstrated the feasibility of simultaneous skipping 
of all eleven exons from exon 45 to 55 using the PMOs in the most effective cocktail set. This 
work represents the first step toward clinical application of PMO-mediated exons 45-55 skipping 
using a mutation-tailored cocktail approach for treating DMD. 
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Results 
Overview of clinical presentation in patients with an exons 45-55 deletion 
We first ensured their clinical profile by summarizing literature published so far, using 52 
patients of which the exons 45-55 deletion was determined by Multiplex Ligation-dependent 
Probe Amplification (MLPA) or a combination of multiplex PCR and Southern blotting (Table 
S1). For profiling, five cases of patients were newly obtained from the Canadian Neuromuscular 
Disease Registry (CNDR). The clinical data confirmed that those with this large deletion 
consistently exhibit mild to asymptomatic phenotypes and retain walking ability up to the late 
seventies. In all patients referred, elevated serum creatine kinase levels were present. Some 
patients were reported to manifest cardiac involvement but not respiratory symptoms. 
Association between exons 45-55 deletion and BMD phenotype 
We analyzed the DMD genotype-phenotype associations using the registries of 4,929 patients 
with deletions determined by MLPA or equivalently accurate methods, and consequent 
phenotypes from the Leiden DMD database. The analyses revealed that more than 67% of 
deletion mutations occur within exons 45-55 (Figure S1A). More BMD phenotype and 
in-frame-type deletions were found in this region compared to those in other regions ranging 
from exon 2 to 44 or from 56 to 78 (Figure S1B and C). In the exons 45-55 region, in-frame 
deletions were statistically more associated with BMD, and the reading frame rule held at a 
higher 97% in BMD compared to other regions (Figure S1D and E). 
Phenotypes found in patients with in-frame deletions involving a frame-shifting exon 
as the first or last one in the region partially explain therapeutic outcome from a single-exon 
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skipping.
11, 17, 23
 An analysis of the proportion of BMD/DMD in in-frame deletions within the 
region first statistically revealed that an in-frame exons 45-55 deletion is more associated with 
the onset of BMD compared to in-frame deletion types starting or ending at an exon 46, 50, 51, 
52 or 55 (Figure 1). In the group of deletions that start or end at exon 45 or 53, no statistical 
difference was found (proportions in individual deletions are available in Table S2). In exon 
55-related in-frame deletions, the exons 45-55 deletion involved more than 90% patients as being 
BMD (75 out of 83), while in other deletions ending at exon 55, 3 out of 5 patients were 
diagnosed with DMD. The result emphasizes the therapeutic relevance of exons 45-55 removal. 
Applicability of exons 45-55 skipping therapy using combinational AO cocktails 
Table 1 and S2 represent the applicability of AO cocktails for exons 45-55 skipping therapy to 
DMD deletion types and phenotypes from the Leiden DMD database. It was revealed that this 
approach can be applied to ~65% of all patients having deletions (n=4,929). Approx. 69% and 
45% of DMD patients carrying out-of- and in-frame deletions, respectively, are amenable to 
exons 45-55 skipping. In DMD with out-of-frame deletions, cocktails of 10 AOs in combination 
permit treatment of the largest population (18% of cases), followed by that of 8 AOs (11%). In 
DMD with in-frame deletions, cocktail 7 AOs were the most required (9%). In terms of the 
phenotypes, ~65% and ~70% of DMD and BMD patients having deletions are treatable with 
exons 45-55 skipping.  
Design of cocktail sets with PMO-modified AOs 
To establish a therapeutic set of AOs that can be used as mutation-tailored cocktails, we designed 
and compared three different cocktail sets composed of PMO-based AOs, each of which 
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contained PMOs assigned to an exon in the exons 45-55 region (Table 2). Individual PMOs 
composing these sets were optimized through a screening method using in silico and in vitro 
approaches, i.e., predicted and actual exon skipping efficiencies, respectively. Cocktail set no. 1 
consisted of 11 30-mer PMOs that were selected to prevent dimerization between PMOs which 
may affect the therapeutic activity and safety in use. Set no. 2 consisted of 11 25-mer PMOs that 
are mostly the human analog versions of sequences used in our previous studies involving mouse 
vivo-PMOs that showed efficient exons 45-55 skipping of the mouse Dmd gene.
20, 24
 Cocktail set 
no. 3 is composed of 12 30-mer PMOs, including 2 PMOs for exon 48 skipping, of which each 
was found to be the most effective for skipping an assigned AO in cell-based screening using 
RT-PCR. The screening process is described in the following sections: 
In silico screening of AO sequences: First, we designed 151 to 413 AO sequences against each 
exon in the exon 45-55 region, covering all possible target sites in individual exons (Table S3). 
According to our AO screening model,
22, 25
 AO length was determined with 30- and 25-mer for 
PMO modification. Exon skipping efficiencies of all sequences were predicted using robust 
algorithms we have previously developed,
22
 providing us with a final ranking that can be used 
for the selection of AO sequences (Table S3). In all exons tested, predicted skipping efficiencies 
of 30-mer AOs were higher than those of 25-mer AOs. 
We also calculated the dimerization potential between AO sequences using a formula 
for the Gibbs free energy of binding (dG) (Table S4). The dimer formation relates to lowered 
exon skipping efficiency and an increase in potential side effects.
26-28
 Along with AO ranking, 
the composition of set no. 1 was determined with 30-mer PMOs having potentially less chances 
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of dimerization, as represented by a higher integration value of dG -363 kcal/mole than that of 
-504 kcal/mole in set no. 3. Using the NCBI BLAST, the theoretical specificity of selected AO 
sequences to a target DMD exon was confirmed by the absence of mRNA sequences of other 
genes identical to the entire AO sequences in the results; 100% identity was found with less than 
56% and 84% of the query covering for 30- and 25-mer sequences, respectively. Sequence 
searching with the GGGenome server revealed fewer genome sites similar to AO sequences with 
an increase in the length (Table S5), indicating that longer 30-mer AOs can work in a more 
sequence-specific manner and have less potential for affecting untargeted transcripts including 
non-coding RNAs that mostly exist in nuclei where AOs work. 
In vitro screening of PMO-based AOs: We next evaluated the actual exon skipping efficiencies 
of AO sequences selected through in silico screening. All the AOs tested here were prepared as 
PMOs that are a promising chemistry as to effectiveness and safety in patients.
5, 7
 In in vitro 
screening, a DMD patient-derived immortalized skeletal muscle cell line carrying an exon 52 
deletion (ID: KM571) was used for testing single-exon skipping except exon 52 skipping, for 
which that with an exons 48-50 deletion (ID: 6594) was used. PMO-mediated single-exon 
skipping as represented by RT-PCR was efficiently induced in all the target exons (Figures 2 
and S2). PMOs that resulted in greater than 20% exon skipping efficiency when tested at 5 or 10 
μM were selected to compose cocktail set no. 3, according to our previous studies, i.e., in vitro 
PMO activity can increase up to 10 μM and such skipping levels can be considered associated 
with dystrophin production as detected by Western blotting.
22, 25
 Effective 30-mer PMOs in each 
exon were found within the top 17 in the ranking of exon skipping efficiencies. While efficient 
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exon skipping was found using a single PMO in most exons, exon 48 skipping was remarkably 
induced with 2 different PMOs. Thus, for cocktail set no. 3, we included 2 PMOs for skipping 
exon 48. Such a synergistic effect was also observed for the skipping of exons 46 and 47. PMOs 
with 25-mer that were previously optimized with vivo-PMOs
20
 were not as effective to induce 
exon skipping efficiencies over 20%, except one for exon 46 skipping and one for exon 52 
skipping that was first in the ranking. 
Exons 45-55 skipping by tailored PMO cocktail approach in DMD muscle cells   
To assess the therapeutic potential of cocktail set nos. 1, 2, and 3 in exons 45-55 skipping, we 
tested its derivative combinational PMO cocktails tailored to treat the different DMD deletions of 
exon(s) 45-52, 48-50, and 52 in immortalized DMD muscle cell lines referred to as 6311, 6594, 
and KM571, respectively (Figure 3). In RT-PCR analyses, as represented by the expression of 
exons 45-55-skipped transcripts, all the derivative cocktails prepared from set no. 1, 2 or 3 
induced 3-, 8-, and 10-exon skipping at doses of 1, 3, and 10 μM per PMO (Figures S3A-C for 
the set nos. 1 and 2; Figure 4A-C for the set no. 3). In all the cocktail sets/combinations, the 
efficiency of exons 45-55 skipping was increased in a dose-dependent manner. PMO cocktail set 
no. 3 was significantly effective at skipping multiple exons in DMD cells, compared to the other 
two sets (Figure 4D-F); using the cocktails at 10 μM each, levels of exons 45-55-skipped mRNA 
reached up to 61%, 43% and 27% on average in 3-, 8-, and 10-exon skipping applications, 
respectively. In the course of testing all the cocktail sets and combinations used, various 
intermediate transcripts that included in-frame and out-of-frame species were produced. The 
expression patterns of these intermediates, however, were unchanged between different 
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concentrations, indicating that the activity of respective PMOs in a cocktail still proportionately 
increases depending on the dose. 
Consistent with the RT-PCR result, dystrophin restoration was induced in DMD 
muscle cells treated with derivative PMO cocktails prepared from set no. 3 when tested at a dose 
of 10 μM per PMO (Figure 5A-C). In the treatment of DMD cells with set no.3 PMO cocktails 
for 3-, 8-, and 10-exon skipping, 14%, 7% and 3% dystrophin of normal levels were induced, 
respectively (Figure 5D-F). For set no. 1 (Figure S3D-F), appreciable dystrophin bands were 
found only in 6311 cells treated with the 3-PMO cocktail, while 8- and 10-exon skipping using 
this set produced very small amounts of dystrophin in 6594 and KM571 cells, having less than 
2% of normal levels. Using set no. 2, no substantial dystrophin bands were detected in any of the 
three DMD cells. Compared to set nos. 1 and 2, the significant effect of set no. 3 on skipping 3, 8, 
or 10 exons was confirmed. 
In vivo efficacy of the cocktail PMOs to skip 11-human DMD exons in a mouse model   
Finally, we tested the in vivo efficacy of exons 45-55 skipping using PMO set no. 3 in a 
humanized mouse model called the hDMD/Dmd-null mouse that has the normal human DMD 
gene and lacks the entire mouse Dmd gene.
25
 In this model, to induce exons 45-55-skipped 
transcripts, all eleven exons need to be simultaneously skipped from the DMD mRNA, which 
allows for evaluating the maximum capability of set no. 3 in in vivo exons 45-55 skipping. In this 
test, we intramuscularly injected 12 PMOs composing set no. 3 as a cocktail at the dose of 20 or 
100 μg in total (1.67 and 8.33 μg of each PMO) into tibialis anterior muscles. One week after 
injection, muscles were harvested for analyses of exon skipping using RT-PCR and of truncated 
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dystrophin production by Western blotting. The result showed exons 45-55 skipping efficiency of 
15% and 22% on average at the low and high dose, respectively (Figure 6). Although skipping 
levels were variable between PMO-treated samples, the dose-dependent effect of the 12-PMO 
cocktail on skipping exons 45-55 in vivo was confirmed. Consistent with a previous report,
29
 
spontaneous DMD exons 45-55-skipped transcripts were detected in saline-treated control 
muscles. In Western blotting, the dystrophin of the treated hDMD/Dmd-null mice was detected 
only at the expected molecular size of the full-length protein as confirmed using samples from 
saline-treated mice and transgenic mice expressing the truncated dystrophin protein lacking the 
exons 45-55 region 30 (Figure S4). 
 
Discussion 
 As shown through analyses of clinical overview and genotype-phenotype association 
(Table S1 and Figure 1), skipping of the entire exons 45-55 region possesses strong rationale to 
be applied for DMD therapy. An important finding from the analysis is that the in-frame deletion 
of the entire exon 45-55 region is statistically associated with the milder BMD when compared 
to other in-frame deletions arising within the region. Given this clinical relevance of the exons 
45-55 deletion, here, we have successfully developed the complete set of PMO-based AOs for 
exons 45-55 skipping from which the PMOs can be used in combination tailored to different 
DMD mutations. One key feature of our cocktail set is a use of the PMO chemistry that has been 
deemed sufficiently safe for human use.
5
 Accordingly, the present study outlined a screening 
model for success in developing multi-exon skipping PMOs. Our model involves a series of in 
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silico pre-screening allowing for the rational selection of PMO sequences, which uses the 
prediction analyses of exon skipping efficiency and potential off-target effects (Table S3-5), 
followed by an in vitro screening with immortalized DMD muscle cells that determines PMOs to 
be included in a cocktail set (Figure 2). With the substantial activity of individual PMOs to skip 
a given exon, the feasibility of the tailored cocktail approach has been proved by the successful 
skipping of 3, 8, and 10 exons (Figure 4), accompanied with dystrophin rescue (Figure 5), in 
three different DMD muscle cells having acceptable mutations. Importantly, while PMO-based 
AOs are typically incompetent for in vivo application, in particular, multi-exon skipping,
31-33
 our 
cocktail PMOs achieved in a humanized mouse model the removal of the maximum 11 exons 
from the normal human DMD mRNA (Figure 6). 
The present results revealed that the effect of cocktail PMOs is largely dependent on 
the sequence/target RNA position of each, highlighting the need for a rigorous selection of 
respective PMOs to compose a cocktail set as done here. For the selection process, a reliable in 
silico pre-screening is indispensable to reasonably narrow down the options of AO sequences 
moving on to a subsequent cell-based screening, out of a few hundred candidates designed as 
encompassing an entire exon region (Table S3). Here, this pre-screening allowed for the 
selection of highly effective PMOs against all the exons in the exons 45-55 region, except exon 
48, using the ranking of predicted exon skipping efficiencies with our in silico tool, 
22, 25
 as 
validated by the actual efficiencies in DMD cells (Figure 2). Although useful to find effective 
PMOs for individual exons in the region of interest, the current tool has some issues including 
that the use is limited to 30- and 25-mer PMO sequences and that the synergistic effect of AOs 
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on the removal of an exon, as found in exon 48 skipping, cannot be predicted. With the 
improvement of the predictive algorithms, in silico pre-screening will increase the opportunity to 
discover more effective PMOs not only for exons 45-55 skipping but also for different 
multi-exon skipping strategies.
2
 Such advanced algorithms are also expected to enable the 
optimization of AO sequences used with other AO chemistries that have greater bioavailability 
in multi-exon skipping, e.g., peptide-conjugated PMOs.
34
 
Along with the optimal design of PMO sequences, appropriate patient cell models in 
the subsequent in vitro screening are an essential tool to evaluate and develop multi-exon 
skipping PMOs. Because rescued dystrophin levels are a primary biomarker of therapeutic 
benefits from exon skipping therapies, cell models need to allow for the quantification of the 
protein by Western blotting that is suggested by the FDA in clinical trials with eteplirsen.
35
 We 
have previously shown in DMD patient fibroblast-converted myotubes, the induction of exons 
45-55 skipped transcripts using 5- and 6-exon skipping PMO cocktails,
21
 but this 
transdifferentiated cell model was not enough to quantify the efficiency at exons 45-55 skipping 
and dystrophin rescue due to low differentiation ability of the cells. In contrast, immortalized 
DMD muscle cells enabled the quantification of dystrophin restoration by Western blotting in the 
test with exons 45-55 skipping PMOs. Because such DMD muscle cell lines available are 
currently limited, the development of those with different mutations amenable to exons 45-55 
skipping are required to further confirm the application of tailored approaches with a cocktail set.  
Following cell-based screening, the in vivo efficacy of the selected AOs needs to be 
examined in an appropriate animal model, such as the humanized mouse model used in this study. 
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Our hDMD/Dmd-null mouse model has the advantage of allowing for the assessment of the 
activity of human-specific AOs in vivo without being confounded by expression of homologous 
mRNA derived from the mouse Dmd gene. In this model, however, treatment effects such as 
dystrophin rescue, histological amelioration, and functional recovery cannot be examined 
because of the lack of dystrophic pathology. The hDMD/Dmd-null mouse model also holds 
normal muscle membrane permeability that can be associated with the lowered efficiency of AO 
uptake. Another concern is that the reactivity of the normal DMD transcript to AOs may be 
different from the mutated versions found in patients. These conditions may affect the estimation 
of the effectiveness of human AOs in patient muscles. Indeed, the dose-dependent effect of the 
PMO cocktail was unclear in the healthy mouse model (Figure 6). As a possible solution to 
these limitations, dystrophic hDMD mouse models having a mutation in the human DMD gene 
have been developed by crossing with mdx mice that have a nonsense mutation in the mouse 
Dmd gene. However, murine dystrophin transcripts are still present in these mice, which may 
pose difficulties in skipping evaluation as described previously.
36, 37 To assess the potential 
benefit of AOs designed for patients, and in particular, dystrophin rescue levels, the development 
of dystrophic humanized mouse models, in which mutations in the human DMD gene cause 
dystrophic phenotypes and the mouse Dmd gene is absent, will be required. 
 With the database analysis, we revealed that cocktail AOs for skipping 10 exons are 
the most required combination to treat DMD deletions, accounted for approx. 17% of those 
(Table 1). In this study, we have demonstrated the 10-exon skipping in a DMD muscle cell line 
with the fourth most common single deletion, an exon 52 deletion (Figures 4 and 5).
2
 Based on 
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the definite effect of individual PMOs in the cocktail set no. 3 on skipping an assigned exon 
(Figure 2), the PMO set has the potential for being adapted to other 10-exon skipping 
approaches targeting different single exon deletions, in particular, an exon 45 deletion that 
creates the largest population of DMD (approx. 6%) (Table S2). This possibility can be further 
supported by the 11-exon skipping in vivo shown in a mouse model with the human DMD gene 
(Figure 6). As such, an exons 45-55-skipping cocktail set is versatile in that it can treat more 
than 65% of DMD patients with deletions (Table 1), whether they are single (e.g. Δ45, Δ51, 
Δ52) or multiple (e.g. Δ45-50, Δ45-52, Δ48-50) exon deletions, and whether they are 
out-of-frame or in-frame. In this study, theoretical applicability of this approach to BMD with 
deletions was also shown, opening a potential avenue of treatment for 70% of the cases, in 
particular, those with severe phenotypes and cardiac impairment that is a leading cause of 
death.
38
 
While exons 45-55 skipping is expected to lead to similar therapeutic outcomes among 
patients regardless of mutation patterns within amenable boundaries, a concern regarding the 
truncated dystrophin produced from exon skipping is the potential structural change it may create 
in the binding site of neuronal nitric oxide synthase (nNOS) encoded by exons 42-45 (Figure 
3B). nNOS and its metabolite NO play a crucial function in directing numerous physiological 
activities of muscle, such as contractile force and blood flow regulation.
39
 In BMD patients, 
reduced expression of nNOS and its mislocalization from the sarcolemma to the cytoplasm have 
been identified.
16, 40
 A recent study with a transgenic mdx mouse model that carries the human 
DMD gene with a deletion of the exons 45-55 region demonstrated normalized activity of nNOS 
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in muscles expressing truncated dystrophin as seen following exons 45-55 skipping therapy 
despite nNOS remaining mislocalized in the cytoplasm.
30
 In this humanized mouse, muscle 
histology and function were also comparable to wild-type mice. The observed rescue effect with 
the truncated dystrophin may be partially associated with the amino acid sequence similarity of 
the hybrid rod domain 17/22 encoded by exons 44/56 to the native rod domain 17 by exon 45 in 
the nNOS binding site.
41
 In addition, the binding sites of F-actin and the sarcolemmal lipid layer 
are partially affected by the exons 45-55 deletion,
42, 43
 which suggests that the resulting 
dystrophin can alter sarcolemmal stability. A hybrid rod similar to the native rod domain 17 
composed of three α-helices has been computationally predicted in some in-frame deletions such 
as the deletions of exons 45-48, 45-51, and 45-55.
44
 Of them, the exons 45-55 deleted dystrophin 
has a structural resemblance to the native protein with 16 rod domains, from the hinge 2 to the 
next hinge 4 (Figure 3B). A future challenge will be to address how the truncation of dystrophin 
impacts interactions with its binding partners and, consequently, on muscle function. This will 
help in better understanding the possible effects of exons 45-55 skipping as a therapy. 
 An issue in PMO cocktail approaches is that the efficiency of exons 45-55 skipping is 
lowered with an increase in the number of target exons or AOs in a cocktail. In the test using 
both cocktail set nos. 1 and 3 comprising 30-mer PMOs, 3- and 10-exon skipping induced the 
highest and lowest efficiencies, respectively (Figure 4). This event did not occur with the 25-mer 
PMO set, probably due to low activity in exons 45-55 skipping. To skip the entirety of exons 45 
to 55, all AOs in a cocktail have to simultaneously bind their target exons of the same 
pre-mRNA but such will not always be the case. In the current cocktail approach using 
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one-to-one interaction of an AO with an exon of a target, the unequable binding of multiple AOs 
to a pre-mRNA is unavoidable, decreasing the efficacy of the intended multi-exon skipping. 
Although the dose escalation of PMOs can improve the chance of simultaneous binding of 
different PMOs, this also increases that of off-target effects in vivo. A possible solution to this 
issue may be to remove the exons 45-55 region as one or a few exon blocks from the pre-mRNA. 
Encouragingly, endogenous exons 45-55 skipped mRNAs have been identified in the normal 
DMD gene.
29
 By revealing a mechanism for this spontaneous multi-exon skipping phenomena, 
exon-block skipping using minimal PMOs can become a practical approach in exons 45-55 
skipping therapy. The strategy will also reduce a concern associated with the formation of 
unintended intermediately skipped transcripts, as found after multi-exon skipping (Figures 4 and 
6) that may have unexpected impacts on therapeutic efficacy. 
 Finally, drug development regulation is another challenge to surmount for the clinical 
translation of tailored cocktail approaches with exons 45-55 skipping AOs. Currently, there is no 
specific regulatory guidance for the development of cocktail drugs using multiple AOs targeting 
different RNA positions in a gene. In this context, an FDA guidance, Codevelopment of Two or 
More New Investigational Drugs for Use in Combination, has been issued on June 2013,
45
 which 
may partially provide some leads for the cocktail AO drug development. Referring to this 
guidance, it is desired to demonstrate that the greater efficacy and better toxicity profile of exons 
45-55 skipping AO cocktails to single-exon skipping AOs in an in vivo (preferable) or in vitro 
model with mutations amenable to both strategies. Second, if the exons 45-55 skipping AOs in 
the cocktail set were to be adapted for patients with different mutation types, clinical trials would 
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need to be respectively performed to separate cocktail compositions, i.e., to the number of 
mutation patterns, which can count 62 of the combination cocktails for 36 out-of-frame and 26 
in-frame deletion patterns found in the region (Table S2). However, it is in practice difficult to 
design such clinical trials with sufficient subjects. One significant issue is that some cocktail 
compositions induce harmful out-of-frame transcripts in healthy volunteers. One solution to 
these is to simply use the complete exons 45-55 skipping cocktail as a single agent regardless of 
mutation type in the region. However, compared to such a cocktail that inevitably contains 
non-therapeutic AOs targeting exons deleted in the patient, it is evident that tailored cocktail 
approaches using only AOs targeting exons that patients retain have a lower risk of side effects. 
In this study, we conclude that PMO-mediated exons 45-55 skipping is doable in tailored 
cocktail approaches and has a potential for treating patients with DMD arising from out-of- and 
in-frame deletion mutations. The approach, however, still needs to overcome certain challenges. 
These include, among others, determining the functional superiority of exons 45-55 skipped 
dystrophin, and the efficacy and safety profile in in vivo models such as transgenic animals with 
dystrophic pathology arising from human DMD mutations, as well as dealing with current drug 
development regulations.
2, 45
 It is also to be noted that patients with other mutation types, e.g., 
duplication and point mutations, require this methodology as some of those can be corrected only 
by skipping multiple exons.
46, 47
 With more research on the approach, we expect that 
mutation-tailored AO cocktails will become a treatment modality not only for DMD but also 
other genetic disorders such as dysferlinopathy with which patients can receive more therapeutic 
benefit from the functional correction of a causative protein.
48
 
  20 
Materials and Methods 
Ethics statement 
Experiments using human cells and animals in this study were performed with approval from the 
Ethics Committee for the Animal Care and Use Committee (ACUC) of the University of Alberta 
and National Center of Neurology and Psychiatry (NCNP). Clinical data of patients enrolled in 
the Canadian Neuromuscular Disease Registry (CNDR) were reviewed with the approval of the 
Health Research Ethics Board of the University of Alberta (Pro00059937). 
 
Patients 
Five new Canadian cases with DMD exons 45-55 deletion were obtained from the CNDR for this 
study. The information of the new cases: date at an examination, ambulatory ability, and cardiac 
involvement, were summarized together with that of cases previously published (Table S1).     
 
Genotype-Phenotype associations and applicability of cocktail treatment 
A total of 16,032 patients in the Leiden Open Variation Database (LOVD v.3.0,  
https://databases.lovd.nl/shared/genes/DMD) were reviewed (accessed June 22
nd
, 2018). Of all 
these patients, 4,929 cases with large exonic deletions (≥ 1 exon) determined with accurate and 
sensitive diagnostic methods were extracted for analyses. These methods include: Multiplex 
Ligation-dependent Probe Amplification (MLPA), Multiplex Amplifiable Probe Hybridization 
(MAPH), array Comparative Genomic Hybridization (array CGH), Next Generation Sequencing 
(NGS), or a combination of multiplex PCR and Southern blotting. In frame type-based analyses, 
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a total of 4,843 cases were used: 3,232 and 1,611 with out-of- and in-frame deletions, 
respectively; 86 cases with deletions starting and/or ending at exon 1 and/or 79, which are not 
applicable to the definition of a frameshift, were excluded from the analyses (Figure S1). In 
phenotype-based analyses, a total of 3,712 data were analyzed: 2,688 of DMD and 1,024 of 
BMD. Registrations without a diagnosis of DMD or BMD were omitted from the analyses. 
Applicability of combinational AO cocktails was analyzed with these populations (Table 1 and 
S2). 
 
Design of antisense sequences 
All possible AO sequences 30- or 25-mer in length were designed for each of the eleven exons 
within exons 45-55 (Table S3). Exon skipping efficiencies of the designed sequences were 
quantitatively predicted using the computational tool we developed previously.
22
 
 
Dimerization potential of AO sequences 
The lowest free energy (dG) of binding of between AOs or individual AOs was predicted with 
RNAstructure web servers (version 6.0.1) (https://rna.urmc.rochester.edu/RNAstructureWeb/). 
Dimerization potential of AO pairs, as shown in Table S4, was formulated as follows: dG of an 
AO pair – (dG of an AO + dG of the other AO). Integrated values of dimerization dG were 
represented as the potential risk of using an AO cocktail. 
 
 
  22 
Specificity of AO sequences 
The specificity of AO sequences was analyzed with both plus and minus strands of the human 
genome (reference ID: GRCh38/hg38) in GGGenome (http://gggenome.dbcls.jp/en/hg38/); the 
parameter was set to explore genomic sequences that differ in 5 or 4 nucleotides with 
mismatches/gaps from given 30- or 25-mer AOs, respectively, which considered >16.7% 
difference from a given AO sequence that may lead to unexpected, off-target effects.
49
  
 
Antisense morpholinos and PMO cocktails   
All AO sequences experimentally tested in this study were synthesized with the PMO chemistry 
by Gene Tools. PMO cocktails were prepared just before use in experiments; respective PMO 
stock vials at 1 mM were heated at 65ºC for 10 min in order to dissociate aggregations and only 
PMOs required to induce exons 45-55 skipping were mixed in transfection media or saline. 
 
Immortalized patient-derived skeletal muscle cells 
Human-derived skeletal muscle cell lines were obtained with the help of Dr. Francesco Muntoni 
of the MRC Centre for Neuromuscular Diseases Biobank (NHS Research Ethics Committee 
reference 06/Q0406/33, HTA license number 12198) in the context of Myobank, affiliated with 
Eurobiobank (European certification). Healthy and DMD patient-derived skeletal muscle cell 
lines were immortalized with CDK4 and Telomerase-expressing pBABE retroviral vectors as 
described previously.
50
 The immortalized DMD muscle cell lines tested were 6311, 6594, and 
KM571 which have deletions of DMD ex45-52, ex48-50, and ex52, respectively. The 
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immortalized healthy muscle cell lines KM155 and 8220 were used as controls.  
 
Transfection of individual and cocktail PMOs 
Immortalized healthy and DMD skeletal muscle cells were grown and differentiated as described 
previously.
25
 Briefly, cells were seeded at 1.7 x 10
4
/cm
2
 in collagen type I-coated culture plates, 
then cultured in a growth medium (GM): DMEM/F12 with skeletal muscle supplement mix 
(Promocell), 20% fetal bovine serum (Gibco), and antibiotics (50 U penicillin and 50 mg/ml 
streptomycin). At 80-90% confluence, media were replaced with a differentiation medium (DM): 
DMEM/F12 supplemented with 2% horse serum (GE Healthcare), 1x insulin-transferrin-sodium 
selenite (ITS) solution (Sigma-Aldrich), and antibiotics. After 3 days in DM, 
myotube-differentiated DMD cells were transfected with a single PMO or multiple PMOs as a 
cocktail at 1, 3, 5, or 10 μM, each containing 6 µM Endo-porter transfection reagent (Gene 
Tools). The same amount of transfection reagent was used regardless of PMO amount according 
to the company’s suggestion. Cocktails of combinational PMOs were prepared just before the 
transfection following the heating procedure described previously. Following the incubation with 
PMOs for 2 days, PMO-containing DM was replaced with regular DM. Three days later, cells 
were harvested for subsequent experiments. 
 
Humanized transgenic mice 
Male transgenic hDMD mice with the full-length normal human DMD gene on mouse 
chromosome 5 (Jackson Laboratory)
51
 were cross-bred with female Dmd-null mice that lack the 
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entire mouse gene in the X-chromosome.
52
 The resulting male offspring, called hDMD/Dmd-null 
mice (hDMD
+/-
; Dmd-null
-/Y
), accordingly expresses full-length dystrophin protein derived from 
the human DMD gene but not from the mouse Dmd gene, which imposes a limitation in 
assessing exon skipping treatment efficacy. The hDMD/Dmd-null mice were used at the age of 
6–16 weeks for testing the in vivo efficacy of a 12-PMO cocktail at skipping 11 exons from 
exons 45 to 55. A humanized mdx mouse model that has an exons 45-55 deletion in the DMD 
gene and expresses exons 45-55 deleted human dystrophin was used as a positive control in 
Western blotting analysis with the muscle samples of hDMD/Dmd-null mice.
30
 
 
PMO cocktail injections 
PMO cocktails with total doses of 20 or 100 μg (1.67 or 8.33 μg per PMO, respectively) in 36 μL 
of saline were injected into the tibialis anterior (TA) muscles of hDMD/Dmd-null mice under 
anesthesia with sodium pentobarbital (Kyoritsu Seiyaku). The same amount of saline was 
intramuscularly injected into the TA muscles as a negative control. One week after the injection, 
mice were euthanized by cervical dislocation, and then the TA muscles injected were collected. 
Muscle samples were snap-frozen as described previously,
24
 and stored at -80ºC until use. 
 
RT-PCR  
Total RNA from cells and frozen TA muscle sections was extracted with Trizol reagent 
(Invitrogen) as described previously.
25
 RT-PCR was performed in a 25-μL mixture containing 
200 ng RNA and 0.2 μM of each primer with the SuperScript III One-Step RT-PCR System 
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(Invitrogen), following manufacturer’s instructions. Primer sequences are listed in Table S6. The 
cycling conditions were optimized depending on the amplicon size of native DMD mRNA in 
each DMD cell line, and it is as follows: 50°C for 5-15 min; 94°C for 2 min; 35-40 cycles at 
94°C for 15 sec, 60°C for 30 sec, and 68°C for 33-118 sec; and 68°C for 5 min. GAPDH or 
Gapdh mRNA was detected as an internal control. PCR products were separated on a 1.5% 
agarose gel and visualized by SYBR Safe DNA Gel Stain (Invitrogen). Skipping percentage was 
calculated as 
Skipped transcript 
Native + Skipped transcript
× 100  for single exon skipping or 
Exons 45−55 skipped transcript 
Native + Intermediates + Skipped transcripts
× 100 for multiple exon skipping using ImageJ (NIH). 
Bands with the expected size of the transcript were excised and purified with a gel extraction kit 
(Promega). Sequencing reactions were performed with Big Dye Terminator v3.1 (Applied 
Biosystems). 
 
Western blotting  
Total protein from cells was extracted with RIPA buffer (Pierce Biotechnology) containing 
protease inhibitors (complete mini EDTA-free, Roche), and concentrations were measured by 
BCA assay (Pierce Biotechnology). Total protein from frozen muscle sections was prepared as 
previously described.
24
 Total protein extracts were loaded onto wells of a NuPAGE Novex 3–8% 
Tris-Acetate Midi Gel (Invitrogen) and separated by SDS-PAGE at 150 V for 75 min for cell 
samples and 150 min for tissues samples. Proteins were transferred onto a PVDF membrane 
(Millipore) by semidry blotting at 20 V for 70 min. The membrane was blocked with PBS 
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containing 0.05% Tween 20 and 2% ECL advance blocking reagent (GE Healthcare) overnight at 
4 ºC. The membrane was incubated with anti-dystrophin C-terminal domain antibody (1:2500, 
ab15277; Abcam) or NCL-DYS1 (1:200, Leica Biosystems) for 1 hour at room temperature. The 
primary antibody was detected with HRP-conjugated IgG H+L secondary antibody (1:10000, 
Invitrogen). Blots were visualized by electrochemiluminescence (GE Healthcare). Expression 
levels of the dystrophin protein induced by PMO cocktails were calculated using a calibration 
curve from 0.12 to 1.8 μg protein of immortalized healthy skeletal muscle cell lines, KM155 or 
8220 (Figure S3H). As a loading control and differentiation marker, α-actinin was detected using 
a primary antibody (Sigma-Aldrich). Myosin heavy chain (MyHC) on the post-transferred gel 
was stained by Coomassie Brilliant Blue as a loading control and as another indicator of muscle 
cell differentiation.  
 
Statistical analysis 
For association analyses between genotypes and phenotypes shown in Figure S1, two-tailed 
Fisher’s exact test (2x2 contingency table) was used with a p-value < 0.05 considered to be 
statistically significant. Differences in phenotype proportions between exons 45-55 deletion and 
other in-frame deletions that start and end at exon(s) within the exons 45-55 region (Figure 1) 
were computed using a two-tailed Fisher’s exact test, and then the resulting p values were 
adjusted for multiple comparisons using the Benjamini-Hochberg procedure: false discovery 
rates (FDRs) of 0.05 or 0.01 were considered as a significant difference. Odds ratios (odds of 
BMD with other in-frame deletions/odds of that with exons 45-55 deletion) and 95% confidence 
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intervals were calculated to quantify differences in the association between BMD and in-frame 
deletion mutations. Statistical tests for efficiency at skipping exons and rescuing dystrophin 
expression were performed using the Tukey-Kramer's or Dunnett’s test. All statistical analyses 
were conducted with R (version 3.5.1). 
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Figure legends 
Figure 1. Associations between in-frame deletion (del.) mutations arising within the exons 
(ex) 45-55 region and consequent phenotypes  
The functionality of different dystrophin forms can partially be explained with the proportion of 
two distinct phenotypes: DMD and BMD in an in-frame deletion. Exon 45, 46, 50, 51, 52, 53, 
and 55 are a frame-shifting one targeted by single-exon skipping therapies. The phenotype ratio 
in in-frame deletions that start/end at a concerned exon and are complete within the exons 45-55 
region are considered associated with therapeutic outcome after exon skipping therapies, 
enabling the comparison of the estimated efficacy between exons 45-55 skipping and single-exon 
skipping strategies. A total of 897 patients carrying acceptable deletions that are determined by 
MLPA or equivalent methods were extracted from the Leiden DMD database. Patients having an 
exons 45-55 del. was not included in the group with ex45 or ex55. FDR-adjusted p values of 0.05 
(*) or 0.01 (**) were considered to be statistically significant compared to ex45-55 del. (Fisher’s 
exact test, Benjamini-Hochberg procedure). Odds ratio (OR) for BMD (odds of other in-frame 
del./odds of ex45-55 del.) and the 95% confidence intervals (CI) were calculated using the 
unconditional Maximum Likelihood Estimate. Statistically significant differences were set at *p 
< 0.05  or **p < 0.01. The information of individual sample sizes are shown in Table S2. 
 
Figure 2. In vitro screening of antisense PMOs for skipping individual DMD exons in the 
exons 45-55 region using RT-PCR 
Efficiencies of exon skipping were tested in an immortalized DMD muscle cell line with an exon 
52 deletion (KM571) except exon 52 skipping for which a DMD muscle cell line with an exons 
48-50 deletion (6594) was utilized. Most PMOs were tested at 5 μM. 10 μM was used for a 
single or combinational PMOs when less than 20% skipping efficiency was found at 5 μM. 
Black and gray bars indicate efficiency at skipping an exon using one and two kinds of PMOs, 
respectively. Data represent mean (SD) from three or four experiments in each. hAc, the human 
version of 25-mer mouse antisense oligos identified in our previous study.
20
 R, a rank with 
30-mer AOs in an exon; r, a rank with 25-mer AOs in an exon; NA, not available; Ete, a PMO 
with eteplirsen sequence. § and # indicate values adapted from our previous reports using an 
identical method to the present study.
22, 25
 All the DNA electrophoresis images and individual 
skipping values used here are shown in Figure S2. 
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Figure 3. Schemes of exons 45-55 skipping using antisense PMO cocktails and the resulting 
truncated dystrophin structure  
(A) Dystrophin mRNA structures in immortalized DMD muscle cell lines (6311, 6594, and 
KM571) and a humanized mouse model, hDMD/Dmd-null, which has the normal human DMD 
gene, and the strategy of exons 45-55 skipping by cocktail PMOs. Boxes indicate exons. The 
shapes denote phase of triplet codons. Exon 48 can be skipped using 2 PMOs from the cocktail 
set 3. (B) A semi-functional dystrophin isoform found in patients with an exons 45-55 deletion or 
following exons 45-55 skipping treatment. In a schematic of wild-type dystrophin, binding 
domains that can partially be affected in the truncated dystrophin are shown: nNOS, the binding 
domain of neuronal nitric oxide synthase; ABD2, actin-binding domain 2; Lipid binding domain 
2, a domain of binding to a phospholipid membrane bilayer. H, hinge region.  
 
Figure 4. Efficiencies of exons 45-55 skipping in immortalized DMD-patient derived 
skeletal muscle cells treated with cocktails of combinational PMOs at 1, 3, and 10 μM each 
tailored to their deletion mutations 
(A-C) DMD exons 45-55-skipping efficiencies using combinational PMOs from the cocktail set 
no. 3; (A) 3-exon skipping in DMD-6311 cells with ex45-52 del., (B) 8-exon skipping in 6594 
cells with ex48-50 del., and (C) 10-exon skipping in KM571 cells with ex52 del. The images of 
tests using the PMO set nos. 1 and 2 are available in Figure S3A-C. M, 100 bp marker; NT, 
non-treated; Mock, a mock 31-mer PMO at 10 μM. (D-F) Quantification of exons 
45-55-skipping induced by combinational PMOs from the cocktail set nos. 1, 2, and 3; (D) 
3-exon skipping against ex45-52 del., (E) 8-exon skipping against ex48-50 del., and (F) 10-exon 
skipping against ex52 del. Efficiency (%) of exons 45-55 skipping following treatment was 
normalized by that of spontaneous one observed in non-treated cells. Data represent the mean 
(SD) from three independent experiments. * p < 0.05, ** p < 0.01 compared to the next lower 
PMO dosage in the same cocktail set. †† p < 0.01 compared to the cocktail set 1 at the same 
PMO dosage. ‡ p < 0.05, ‡‡ p < 0.01 compared to the cocktail set 2 at the same dosage (Tukey–
Kramer test).  
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Figure 5. Dystrophin restoration in DMD muscle cells treated with 3-, 8- or 10-exon 
skipping using cocktail PMOs 
Rescued dystrophin in (A) DMD-6311 cells treated with 3 PMOs, (B) 6594 cells with 8 PMOs, 
and (C) KM571 cells with 11 PMOs (10 μM each) from the cocktail set no. 3 was measured by 
Western blotting with the anti-dystrophin C-terminal domain antibody. Total protein of 9 μg from 
6311 cells and 18 μg from 6594 or KM571 cells was loaded. The band images with the cocktail 
set nos. 1 and 2 are available in Figure S3D-F. To calculate the expression levels in DMD cells, 
healthy muscle cell lines, KM155 and 8220 were used for a standard curve in the range from 
1.3% to 20% protein of that of DMD cells (averaged R
2
 = 0.97, SD 0.028, representatives are 
shown in Figure S3G). Total protein amount of KM155 cells was adjusted to the same amount 
of DMD cells using the total protein of non-treated DMD cells. (D-F) Quantification of 
dystrophin induced by combinational PMOs from the cocktail set no. 1, 2 or 3 in (D) 6311 cells 
with ex45-52 del., (E) 6594 with ex48-50 del., and (F) KM571 with ex52 del. Expression levels 
of rescued dystrophin were normalized by that of spontaneous one observed in non-treated DMD 
cells and were calculated with a standard curve using the 8220 healthy muscle cells for the 
comparison. Data represent the mean (SD) from three independent experiments. **, p < 0.01 
compared to the set 1; ††, p < 0.01 compared to the set 2 (Tukey–Kramer test).  
 
Figure 6. In vivo exons 45-55 skipping using 12 PMOs of the cocktail set no. 3 by the 
intramuscular (i.m.) injection into tibialis anterior (TA) muscles of a humanized mouse 
model with the normal human DMD gene and without the entire mouse Dmd gene 
(hDMD/Dmd-null mouse) 
A cocktail of 12 PMOs at 20 and 100 μg in total (1.67 and 8.33 μg each PMO, respectively) was 
injected once into left and right TA muscles of mice, respectively. One week after the injection, 
the muscles were harvested. The efficiency (%) of exons 45-55 skipping was analyzed by 
RT-PCR as shown in the bottom of the image. M, 100 bp marker. (A) Representative images of 
in vivo exons 45-55 skipping in individual TA muscles of hDMD/Dmd-null mice. (B) 
Quantification of exons 45-55 skipped mRNA levels as represented by the mean (SEM). n = 5 in 
injected TA muscles, n = 4 in control TA muscles. The statistical significance was set at * p < 
0.05 (Dunnett's test). 
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Table 1. Applicability of exons 45-55 skipping to patients with deletion mutaions. 
 
Exon no.  
to be  
skipped  
% applicability of exons 45-55 skipping to: 
Del. total 
(n=4929) 
DMD 
BMD 
(n=1030) 
Out-of-frame  
del. (n=2425) 
In-frame  
del. (n=263) 
DMD total 
(n=2744) 
10 14.1 18.4 5.7 16.8 5.3 
9 6.9 8.0 8.4 7.9 4.8 
8 13.8 10.9 7.3 10.3 26.8 
7 8.7 4.3 9.2 4.7 19.8 
6 6.2 7.1 5.0 6.7 5.1 
5 6.0 9.1 2.3 8.3 0.5 
4 2.3 2.5 2.3 2.4 1.4 
3 3.7 6.1 0.4 5.4 0.1 
2 1.8 0.0 4.2 0.4 6.5 
1 1.8 2.6 0.0 2.3 0.1 
Total 65.2 69.0 44.8 65.3 70.4 
Deletion (del.) total includes patients diagnosed with DMD or BMD, and those not determined 
with either. Deletion types in DMD consist of deletions in the region from exon 2 to 78 where 
the reading frame rule is applied. DMD total and BMD include patients carrying deletions in 
exons 1-79. The applicability to individual deletions is shown in Table S2. 
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Table 2. PMO sequences composing cocktail sets and its rank with exon skipping efficiency 
predicted in a computational tool 
Cocktail Name AO sequence (5' to 3') 
Rank 
within  
an exon 
Predicted  
skipping % 
Set no. 1 Ex45_Ac9_30mer GACAACAGTTTGCCGCTGCCCAATGCCATC 2 76.2 
 
Ex46_Ac52_30mer GTTATCTGCTTCCTCCAACCATAAAACAAA 1 66.7 
 
Ex47_Ac50_30mer GCACTTACAAGCACGGGTCCTCCAGTTTCA 9 53.0 
 
Ex48_Ac7_30mer CAATTTCTCCTTGTTTCTCAGGTAAAGCTC 8 65.0 
 
Ex49_Ac17_30mer ATCTCTTCCACATCCGGTTGTTTAGCTTGA 1 90.0 
 
Ex50_Ac19_30mer GTAAACGGTTTACCGCCTTCCACTCAGAGC 20 76.6 
 
Ex51_Ac5_30mer AGGTTGTGTCACCAGAGTAACAGTCTGAGT 4 73.0 
 
Ex52_Ac24_30mer GGTAATGAGTTCTTCCAACTGGGGACGCCT 25 90.1 
 
Ex53_Ac9_30mer GTTCTTGTACTTCATCCCACTGATTCTGAA 2 73.9 
 
Ex54_Ac42_30mer GAGAAGTTTCAGGGCCAAGTCATTTGCCAC 1 62.0 
 
Ex55_Ac0_30mer TCTTCCAAAGCAGCCTCTCGCTCACTCACC 1 120.4 
Set no. 2 hEx45_Ac4_25mer TGCCGCTGCCCAATGCCATCCTGGA 4 42.7 
  hEx46_Ac103_25mer CTTTTAGTTGCTGCTCTTTTCCAGG 34 32.8 
  hEx47_Ac21_25mer ATTGTTTGAGAATTCCCTGGCGCAG 58 8.2 
  hEx48_Ac-2_25mer TTCTCAGGTAAAGCTCTGGAAACCT NA NA 
  hEx49_Ac23_25mer AATCTCTTCCACATCCGGTTGTTTA 31 41.9 
  hEx50_Ac47_25mer CTGCTTTGCCCTCAGCTCTTGAAGT 44 36.4 
  hEx51_Ac65_25mer ACATCAAGGAAGATGGCATTTCTAG 133 -5.4 
  hEx52_Ac3_25mer GCCTCTGTTCCAAATCCTGCATTGT 1 74.6 
  hEx53_Ac43_25mer ATTCAACTGTTGCCTCCGGTTCTGA 67 7.3 
  hEx54_Ac22_25mer GCCACATCTACATTTGTCTGCCACT 33 12.8 
  hEx55_Ac83_25mer GCAGTTGTTTCAGCTTCTGTAAGCC 53 32.7 
Set no. 3 Ex45_Ac9_30mer The same as the AO in the set 1 2 76.2 
 
Ex46_Ac93_30mer AGTTGCTGCTCTTTTCCAGGTTCAAGTGGG 11 60.4 
 
Ex47_Ac13_30mer GTTTGAGAATTCCCTGGCGCAGGGGCAACT 17 49.2 
 
Ex48_Ac7_30mer The same as the AO in the set 1 8 65.0 
 
Ex48_Ac78_30mer CAGATGATTTAACTGCTCTTCAAGGTCTTC 35 44.5 
 
Ex49_Ac17_30mer The same as the AO in the set 1 1 90.0 
 
Ex50_Ac19_30mer The same as the AO in the set 1 16 76.6 
 
Ex51_Ac0_30mer GTGTCACCAGAGTAACAGTCTGAGTAGGAG 2 80.1 
 
Ex52_Ac24_30mer The same as the AO in the set 1 11 90.1 
 
Ex53_Ac26_30mer CCTCCGGTTCTGAAGGTGTTCTTGTACTTC 1 75.2 
 
Ex54_Ac42_30mer The same as the AO in the set 1 1 62.0 
  Ex55_Ac0_30mer The same as the AO in the set 1 1 120.4 
The cocktail set no. 2 was composed of human PMOs that are analog ones of mouse vivo-PMOs 
developed in our previous study,
20
 except hEx52_Ac3_25mer. Underlined bases indicate human 
nucleotides substituted from mouse ones. The number following Ac indicates a distance from an 
acceptor splice site. NA, not available in the predictive tool used here. 






